Cargando…
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
BACKGROUND: Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Si...
Autores principales: | Fucà, Giovanni, Cohen, Romain, Lonardi, Sara, Shitara, Kohei, Elez, Maria Elena, Fakih, Marwan, Chao, Joseph, Klempner, Samuel J, Emmett, Matthew, Jayachandran, Priya, Bergamo, Francesca, García, Marc Díez, Mazzoli, Giacomo, Provenzano, Leonardo, Colle, Raphael, Svrcek, Magali, Ambrosini, Margherita, Randon, Giovanni, Shah, Aakash Tushar, Salati, Massimiliano, Fenocchio, Elisabetta, Salvatore, Lisa, Chida, Keigo, Kawazoe, Akihito, Conca, Veronica, Curigliano, Giuseppe, Corti, Francesca, Cremolini, Chiara, Overman, Michael, Andre, Thierry, Pietrantonio, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811606/ https://www.ncbi.nlm.nih.gov/pubmed/35110358 http://dx.doi.org/10.1136/jitc-2021-004001 |
Ejemplares similares
-
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023) -
BRAF
(V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023) -
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021) -
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019) -
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)